Management of Pheochromocytomas and Paragangliomas: A Case-Based Review of Clinical Aspects and Perspectives

Overview

Journal J Clin Med

Specialty General Medicine

Date 2022 May 14

PMID 35566714

Authors

Bartosz Kamil Sobocki

Adrian Perdyan

Olga Szot

Jacek Rutkowski

Affiliations

Soon will be listed here.

Abstract

Paraganglioma and pheochromocytoma are rare medical conditions. Thus, there are still a small number of studies, clinical trials, and evidence-based data in this field. This makes clinical decisions more difficult. In this study, we present a case report enriched with a short review of available essential clinical data, indicating the need for constant metoxycatecholamine level observation and a proper diagnostic imaging approach, especially in terms of ongoing pandemics. Our research also provides a summary of the molecular background of these diseases, indicating their future role in clinical management. We analyzed the ClinicalTrials.gov dataset in order to show future perspectives. In this paper, the use of the PET-CT before MRI or CT is proposed in specific cases during diagnosis processes contrary to the guidelines. PET-CT may be as effective as standard procedures and may provide a faster diagnosis, which is important in periods with more difficult access to health care, such as during the COVID-19 pandemic.

Citing Articles

F-FDG PET/CT and Ga-DOTATATE PET/CT Findings of Polycystic Kidney-derived Paraganglioma.

Tosunoglu Z, Baykal Koca S, Ergul N, Cermik T, Arsla E Mol Imaging Radionucl Ther. 2024; 33(3):182-184.

PMID: 39373189 PMC: 11589347. DOI: 10.4274/mirt.galenos.2024.03264.

Anesthetic Management of Robot-Assisted Laparoscopic Surgery of Pheochromocytoma.

Suryawanshi C, Varma S, Vazhakalayil S Cureus. 2024; 16(2):e53850.

PMID: 38465083 PMC: 10924627. DOI: 10.7759/cureus.53850.

Primary non-functional pancreatic paraganglioma: A case report and review of the literature.

Zhao Z, Guo Y, Liu L, Zhang L, Li S, Yang J J Int Med Res. 2022; 50(12):3000605221143023.

PMID: 36562124 PMC: 9793047. DOI: 10.1177/03000605221143023.

Neuroendocrine Tumors: Challenges and Future Perspectives.

Lamberti G, La Salvia A J Clin Med. 2022; 11(15).

PMID: 35955968 PMC: 9369270. DOI: 10.3390/jcm11154351.

References

Lazzerini M, Barbi E, Apicella A, Marchetti F, Cardinale F, Trobia G . Delayed access or provision of care in Italy resulting from fear of COVID-19. Lancet Child Adolesc Health. 2020; 4(5):e10-e11. PMC: 7146704. DOI: 10.1016/S2352-4642(20)30108-5. View

Fankhauser M, Bechmann N, Lauseker M, Goncalves J, Favier J, Klink B . Synergistic Highly Potent Targeted Drug Combinations in Different Pheochromocytoma Models Including Human Tumor Cultures. Endocrinology. 2019; 160(11):2600-2617. PMC: 6795182. DOI: 10.1210/en.2019-00410. View

Peng S, Zhang J, Tan X, Huang Y, Xu J, Silk N . The VHL/HIF Axis in the Development and Treatment of Pheochromocytoma/Paraganglioma. Front Endocrinol (Lausanne). 2020; 11:586857. PMC: 7732471. DOI: 10.3389/fendo.2020.586857. View

Zitzmann K, von Ruden J, Brand S, Goke B, Lichtl J, Spottl G . Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Cancer Lett. 2010; 295(1):100-9. DOI: 10.1016/j.canlet.2010.02.018. View

Lee S, Gross S, Pfaff H, Dresen A . Waiting time, communication quality, and patient satisfaction: An analysis of moderating influences on the relationship between perceived waiting time and the satisfaction of breast cancer patients during their inpatient stay. Patient Educ Couns. 2019; 103(4):819-825. DOI: 10.1016/j.pec.2019.11.018. View

Oudijk L, de Krijger R, Rapa I, Beuschlein F, de Cubas A, Dei Tos A . H-RAS mutations are restricted to sporadic pheochromocytomas lacking specific clinical or pathological features: data from a multi-institutional series. J Clin Endocrinol Metab. 2014; 99(7):E1376-80. DOI: 10.1210/jc.2013-3879. View

Gonzalez I, Vallejo A, Guerrero Lizcano E, Pabon Giron A . Adrenal Pheochromocytoma Treated With Stereotactic Body Radiation Therapy. Cureus. 2021; 13(1):e12456. PMC: 7856918. DOI: 10.7759/cureus.12456. View

Szeberenyi J, Fabian Z, Torocsik B, Kiss K, Csatary L . Newcastle disease virus-induced apoptosis in PC12 pheochromocytoma cells. Am J Ther. 2003; 10(4):282-8. DOI: 10.1097/00045391-200307000-00008. View

Papewalis C, Kouatchoua C, Ehlers M, Jacobs B, Porwol D, Schinner S . Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma. Mol Cell Endocrinol. 2010; 335(1):69-77. DOI: 10.1016/j.mce.2010.05.021. View

10.

Chuk M, Widemann B, Minard C, Liu X, Kim A, Bernhardt M . A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018; 65(8):e27077. PMC: 6082380. DOI: 10.1002/pbc.27077. View

11.

Feng N, Zhang W, Wu X . Clinicopathological analysis of paraganglioma with literature review. World J Gastroenterol. 2009; 15(24):3003-8. PMC: 2702108. DOI: 10.3748/wjg.15.3003. View

12.

Morin A, Goncalves J, Moog S, Castro-Vega L, Job S, Buffet A . TET-Mediated Hypermethylation Primes SDH-Deficient Cells for HIF2α-Driven Mesenchymal Transition. Cell Rep. 2020; 30(13):4551-4566.e7. DOI: 10.1016/j.celrep.2020.03.022. View

13.

Liu P, Li M, Guan X, Yu A, Xiao Q, Wang C . Clinical Syndromes and Genetic Screening Strategies of Pheochromocytoma and Paraganglioma. J Kidney Cancer VHL. 2019; 5(4):14-22. PMC: 6308242. DOI: 10.15586/jkcvhl.2018.113. View

14.

Andre F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo H . Alpelisib for -Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2019; 380(20):1929-1940. DOI: 10.1056/NEJMoa1813904. View

15.

Ni H, Htet A . Adrenal cortical carcinoma masquerading as pheochromocytoma: a case report. Ecancermedicalscience. 2012; 6:277. PMC: 3493057. DOI: 10.3332/ecancer.2012.277. View

16.

Zhang X, Wang X, Qin L, Xu T, Zhu Z, Zhong S . The dual mTORC1 and mTORC2 inhibitor PP242 shows strong antitumor activity in a pheochromocytoma PC12 cell tumor model. Urology. 2014; 85(1):273.e1-7. DOI: 10.1016/j.urology.2014.09.020. View

17.

Lenders J, Kerstens M, Amar L, Prejbisz A, Robledo M, Taieb D . Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020; 38(8):1443-1456. PMC: 7486815. DOI: 10.1097/HJH.0000000000002438. View

18.

Jimenez C, Subbiah V, Stephen B, Ma J, Milton D, Xu M . Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. Cancers (Basel). 2020; 12(8). PMC: 7465458. DOI: 10.3390/cancers12082307. View

19.

Makeieff M, Thariat J, Reyt E, Righini C . Treatment of cervical paragangliomas. Eur Ann Otorhinolaryngol Head Neck Dis. 2012; 129(6):308-14. DOI: 10.1016/j.anorl.2012.03.006. View

20.

Toledo R . New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2017; 24(9):C9-C19. DOI: 10.1530/ERC-16-0479. View